News|Articles|May 30, 2025
NeurologyLive® Friday 5 — May 30, 2025
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 30, 2025.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Tracking Therapeutic Progress of Gene-Editing Agent PBGENE-DMD for Duchenne Muscular Dystrophy
Jeff Smith, PhD, chief executive officer at Precision Biosciences, explained the clinical potential and gene-editing mechanism of PBGENE-DMD, a one-time therapy targeting dystrophin mutations in Duchenne muscular dystrophy.
2: Overviewing Phase 2 Data of Imlifidase in Guillain-Barré Syndrome: Elisabeth Sonesson, PhD
The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]
3: Holistic Strategies and to Promote Remyelination in MS
In this roundtable episode, neurologists Paul Tesar, PhD, and Ari Green, MD, examine the plausibility, limitations, and risks of holistic approaches to remyelination—and what patients should prioritize or avoid.
4: NeuroVoices: Elisabeth Sonesson, PhD, on Imlifidase’s Targeted, Fast-Acting Approach to GBS
The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.
5: Screening and Managing Comorbidities for Patients With Duchenne Muscular Dystrophy
In this NeurologyLive Insights episode, Diana Castro, MD, explores the comprehensive comorbidities of Duchenne Muscular Dystrophy, including cognitive, respiratory, and nutritional challenges faced by patients.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4